Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon Jun 26, 2019 4:45pm
62 Views
Post# 29866988

RE:RE:RE:RE:RE:RE:RE:RE:Rutherrin

RE:RE:RE:RE:RE:RE:RE:RE:RutherrinEoganacht ... Accurate.

______________________

Eoganacht - (6/26/2019 4:02:09 PM) 
RE:RE:RE:RE:RE:RE:RE:Rutherrin
The link to the online journal was provided by Enrique earlier today:

Neuro-Oncology Advances

ACCEPTED MANUSCRIPT
 
Efficacy of Ruthenium coordination complex based Rutherrin in a pre-clinical rat glioblastoma(GBM) model
 
Manjunatha Akathatti Munegowda  Carl Fisher  Daniel Molehuis  Warren Foltz Mark Roufaiel  Jay Bassan  Mark Nitz  Arkady Mandel  Lothar Lilge
 
Published: 28 May 2019
 
If you click on the PDF link and go to the last paragraph of page 20 you will see:
 
"Rutherrin-PDT was well tolerated, providing safe and effective treatment of RG-2 glioma. Rutherrin mediated PDT response appears superior to ALA-PpIX mediated PDT. In our
unpublished clinical study, photosensitizer present in Rutherrin formulation has not shown any phototoxicity, excluding patients from avoiding light sources. With these positive PDT results
and the ability to absorb light at longer wavelengths, resistance photobleaching, Rutherrin is a promising photosensitizer formulation to target brain cancer."




hydrocarbss wrote:fredgoodwinson wrote

'In our unpublished clinical study, photosensitizer present in Rutherrin formulation has not shown any phototoxicity, excluding patients from avoiding light sources.'

I questioned the source.

B$ reply:


billiondolarman - (6/26/2019 3:24:17 PM) 
RE:RE:RE:RE:RE:Rutherrin
Todays news release. If you take the time to read it.>>>BDM

My response:  That statement, re: an unpublished clinical study...

cannot be found in the news release of June 26, 2019 from Theralase.

Bullboard Posts